These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 20598905

  • 1. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L.
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 5. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
    Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R.
    Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
    [Abstract] [Full Text] [Related]

  • 6. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM.
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [Abstract] [Full Text] [Related]

  • 7. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y, Obara Y, Hara K, Yamashiro H, Kurosawa N, Takada D.
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [Abstract] [Full Text] [Related]

  • 13. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I, Hutchison AJ.
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [Abstract] [Full Text] [Related]

  • 14. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators.
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [Abstract] [Full Text] [Related]

  • 15. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Mar; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 16. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
    Arenas MD, Rebollo P, Malek T, Moledous A, Gil MT, Alvarez-Ude F, Morales A, Cotilla E.
    J Nephrol; 2010 Mar; 23(6):683-92. PubMed ID: 20540040
    [Abstract] [Full Text] [Related]

  • 17. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA, Burke SK, Dillon MA.
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [Abstract] [Full Text] [Related]

  • 18. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF, Joy MS, LAM-308 Study Group.
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [Abstract] [Full Text] [Related]

  • 19. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K, Matsuda E, Sekino M, Hasegawa Y, Kamo Y, Kikuchi N, Sekino H.
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T, Hong Z, Matsunaga T, Kaneko Y, Taru Y.
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.